The Organic Chemistry of Drug Design and Drug Action The Organic Chemistry of Drug Design and Drug Action

The Organic Chemistry of Drug Design and Drug Action

    • $92.99
    • $92.99

Publisher Description

The Organic Chemistry of Drug Design and Drug Action, Third Edition, represents a unique approach to medicinal chemistry based on physical organic chemical principles and reaction mechanisms that rationalize drug action, which allows the reader to extrapolate those core principles and mechanisms to many related classes of drug molecules. This new edition reflects significant changes in the process of drug design over the last decade. It preserves the successful approach of the previous editions while including significant changes in format and coverage.

New to this edition: Updates to all chapters, including new examples and referencesChapter 1 (Introduction): Completely rewritten and expanded as an overview of topics discussed in detail throughout the bookChapter 2 (Lead Discovery and Lead Modification): Sections on sources of compounds for screening including library collections, virtual screening, and computational methods, as well as hit-to-lead and scaffold hopping; expanded sections on sources of lead compounds, fragment-based lead discovery, and molecular graphics; and deemphasized solid-phase synthesis and combinatorial chemistryChapter 3 (Receptors): Drug-receptor interactions, cation-p and halogen bonding; atropisomers; case history of the insomnia drug suvorexantChapter 4 (Enzymes): Expanded sections on enzyme catalysis in drug discovery and enzyme synthesisChapter 5 (Enzyme Inhibition and Inactivation): New case histories: for competitive inhibition, the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib and Abelson kinase inhibitor, imatinibfor transition state analogue inhibition, the purine nucleoside phosphorylase inhibitors, forodesine and DADMe-ImmH, as well as the mechanism of the multisubstrate analog inhibitor isoniazidfor slow, tight-binding inhibition, the dipeptidyl peptidase-4 inhibitor, saxagliptinChapter 7 (Drug Resistance and Drug Synergism): This new chapter includes topics taken from two chapters in the previous edition, with many new examplesChapter 8 (Drug Metabolism): Discussions of toxicophores and reactive metabolitesChapter 9 (Prodrugs and Drug Delivery Systems): Discussion of antibody–drug conjugates

GENRE
Science & Nature
RELEASED
2014
March 29
LANGUAGE
EN
English
LENGTH
536
Pages
PUBLISHER
Academic Press
SELLER
Elsevier Ltd.
SIZE
72.5
MB
The Practice of Medicinal Chemistry The Practice of Medicinal Chemistry
2003
Small Molecule Drug Discovery Small Molecule Drug Discovery
2019
Chiral Drugs Chiral Drugs
2011
Chemistry of Biologically Potent Natural Products and Synthetic Compounds Chemistry of Biologically Potent Natural Products and Synthetic Compounds
2021
Organofluorine Compounds in Biology and Medicine Organofluorine Compounds in Biology and Medicine
2015
Chirality in Drug Design and Synthesis Chirality in Drug Design and Synthesis
2013
The Organic Chemistry of Drug Design and Drug Action The Organic Chemistry of Drug Design and Drug Action
2012
Manuale di chimica farmaceutica Manuale di chimica farmaceutica
2015
Organic Chemistry of Enzyme-Catalyzed Reactions, Revised Edition Organic Chemistry of Enzyme-Catalyzed Reactions, Revised Edition
2002